Vivian G. Oehler

Appointments and Affiliations

 
 
Fred Hutchinson Cancer Research Center
Clinical Research Division
Assistant Member, Appointed: 2008
 
University of Washington
School of Medicine
Medicine
Hematology
Assistant Professor, Appointed: 2008
Professional Headshot of Vivian G. Oehler

Mailing Address

1100 Fairview Ave. North
D5-100
Seattle, Washington 98109
United States

Contact

Phone: (206) 667-1340
Fax: (206) 667-2917

voehler@uw.edu

http://labs.fhcrc.org/oehler/index.html

Degrees

Fellowship Training, University of Washington, Hematology and Oncology, 2004.
Fellowship Training, Fred Hutchinson Cancer Research Center, Hematology and Oncology, 2004.
Residency Training, University of Washington, Medicine, 2000.
M.D., Case Western Reserve University, Medicine, 1997.
B.A., Harvard University, Government, 1989.

Research Interests

Current Clinical Interests
Myeloproliferative and myelodysplastic disorders; acute myeloid leukemia

Current Research Interests
Mechanisms of leukemia disease initiation/progression and therapy resistance, new agents in the treatment of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML).

Research Description

Tyrosine kinase inhibitors such as imatinib, dasatinib and nilotinib have dramatically altered treatment strategies in chronic myeloid leukemia (CML). Outcomes for early (or chronic phase) disease are excellent. However, a significant minority of chronic phase CML patients and many advanced CML patients develop resistance to therapy.

In the laboratory we are examining mechanisms involved in CML disease progression and the effects of tyrosine kinase inhibitor therapy on the underlying natural history of CML disease. In the clinic we are pursuing studies of new agents in the treatment of CML and AML.

CML provides a unique disease model in which to apply a translational approach. Using microarray-based gene and microRNA expression studies of a large group of CML patients, we have identified expression changes in patients that are highly associated with disease progression and therapy resistance. We have identified similar changes in AML. We are using these data to investigate several questions including: can we identify candidates that predict which patients are at risk for early therapy failure or disease progression and can we determine how these genes and their targets cause disease progression and therapy resistance?

To answer the first question we are investigating a group of prognostic markers at diagnosis that can identify patients at risk for early disease progression or therapy failure. To answer the second question, the most promising candidates derived from our patient-based studies are examined in vitro and in vivo to better understand their possible function in disease progression and therapy resistance, and to define pathways that can be targeted by existing or novel therapies.

Languages

Reading, Writing, Speaking

German: Fluent, Functional, Fluent

Memberships

American Society of Hematology
Southwest Oncology Group

Honors and Awards

Honor Medical Society, Alpha Omega Alpha
Clinical/Translational Research Scholar Award, American Society of Hematology - Fellow Award

Previous Positions

2008-2008, Acting Assistant Professor, University of Washington, School of Medicine, Medicine, Hematology
2005-2008, Associate in Clinical Research, Fred Hutchinson Cancer Research Center, Clinical Research Division
2004-2005, Research Associate, Fred Hutchinson Cancer Research Center
2004-2008, Acting Instructor, University of Washington, School of Medicine, Medicine, Hematology

Funding

  • National Institutes of Health (NIH): Integrating Diagnostics with Therapeutic Strategies in Chronic Myeloid Leukemia, 2009 to 2014.
  • American Society of Hematology: Progression and resistance in chronic myeloid leukemia, 2009 to 2012.
  • NIGMS: Prediction and Network Construction Using High-Throughput Data, 2009 to 2012.
  • Leukemia and Lymphoma Society: Expression, function, and regulation of genes associated with chronic myeloid leukemia progression and imatinib mesylate resistance, 2008 to 2011.

 

Recent Publications

2014
2013
2011
2010
2009